Arena’s net loss was $22.91m, or $0.16 loss per diluted share, compared to net loss of $28.76m, or $0.28 loss per diluted share, for the same period in 2010.
For the six months ended 30 June 2011, the company reported total revenues of $7.18m, compared to $4.97m for the same period in 2010.
The company has reported net loss of $62.81m or 0.49 loss per diluted share for the six months ended 30 June 2011, as compared to $60.03m or $0.60 loss per diluted share for the same period in 2010.
Arena president and CEO Jack Lief said they view the results from the Pathology Working Group’s re-adjudication and the CSF study as important steps toward our planned response to the lorcaserin complete response letter.